Suppr超能文献

ε和κ阿片受体参与布瑞马唑辛对小鼠甩尾反应的抑制作用。

Involvement of epsilon and kappa opioid receptors in inhibition of the tail-flick response induced by bremazocine in the mouse.

作者信息

Tseng L F, Collins K A

机构信息

Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee.

出版信息

J Pharmacol Exp Ther. 1991 Oct;259(1):330-6.

PMID:1656027
Abstract

Bremazocine, a benzomorphan, has been reported to have kappa, mu and epsilon opioid receptor binding activities. The present studies were then designed to determine what types of opioid receptors and neurotransmitters were involved in inhibiting the tail-flick response induced by bremazocine in male ICR mice. U50, 488H, a prototypic kappa agonist, was used for comparison. Bremazocine, at doses from 0.1 to 1 microgram given i.c.v., dose-dependently inhibited the tail-flick response. The paw-licking hot plate response, even at high doses of bremazocine, was not completely inhibited. The inhibition of the tail-flick response induced by bremazocine (1 microgram) given i.c.v. was blocked by i.c.v. coadministration of beta-endorphin-(1-27) (3 and 6 micrograms), an epsilon opioid receptor antagonist and norbinaltorphimine (4 micrograms), a kappa opioid receptor antagonist. On the other hand, the inhibition induced by i.c.v. U50,488H (40 micrograms) was blocked by i.c.v. norbinaltorphimine, but not beta-endorphin-(1-27). D-Phe-Cys-Tyr-D-Try-Orn-Thr-Pen-Thr-NH2 (CTOP; 0.5 microgram) and beta-funaltrexamine (beta-FNA; 2.5 micrograms), selective mu opioid receptor antagonists, and ICI 174,864 (10 micrograms), a delta-opioid receptor antagonist, which blocked the effects induced by DAMGO (16 ng) and DPDPE (20 micrograms), respectively, did not block inhibition of the tail-flick response induced by bremazocine (1 microgram) given i.c.v. The inhibition of the tail-flick response induced by i.t. administration of bremazocine (1 microgram) was blocked by i.t. coadministration of norbinaltorphimine but not CTOP, ICI 174,864, or beta-endorphin-(1-27).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

布马佐辛是一种苯并吗啡烷,据报道具有κ、μ和ε阿片受体结合活性。本研究旨在确定在雄性ICR小鼠中,布马佐辛抑制甩尾反应涉及何种类型的阿片受体和神经递质。使用原型κ激动剂U50,488H作为对照。脑室内注射剂量为0.1至1微克的布马佐辛,可剂量依赖性地抑制甩尾反应。即使在高剂量的布马佐辛作用下,舔爪热板反应也未被完全抑制。脑室内注射1微克布马佐辛所诱导的甩尾反应抑制作用,可被脑室内共同注射ε阿片受体拮抗剂β-内啡肽-(1-27)(3微克和微克)和κ阿片受体拮抗剂诺宾那托啡(4微克)所阻断。另一方面,脑室内注射40微克U50,488H所诱导的抑制作用,可被脑室内注射诺宾那托啡阻断,但不能被β-内啡肽-(1-27)阻断。选择性μ阿片受体拮抗剂D-苯丙氨酸-半胱氨酸-酪氨酸-D-色氨酸-鸟氨酸-苏氨酸-青霉胺-苏氨酸-NH2(CTOP;0.5微克)和β-芬太尼丁胺(β-FNA;2.5微克),以及δ阿片受体拮抗剂ICI 174,864(10微克),它们分别阻断了由DAMGO(16纳克)和DPDPE(20微克)所诱导的效应,但并未阻断脑室内注射1微克布马佐辛所诱导的甩尾反应抑制作用。脊髓内注射1微克布马佐辛所诱导的甩尾反应抑制作用,可被脊髓内共同注射诺宾那托啡阻断,但不能被CTOP、ICI 174,864或β-内啡肽-(1-27)阻断。(摘要截短于250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验